Search
01/02/2022
Urinary Proteomic Signature in Acute Decompensated Heart Failure: Advances into Molecular Pathophysiology
Diaz-Riera, E, Garcia-Arguinzonis, M, Lopez, L, Garcia-Moll, X, Badimon, L, Padro, T. Urinary Proteomic Signature in Acute Decompensated Heart Failure: Advances into Molecular Pathophysiology. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2022; 23(4)DOI:10.3390/ijms23042344. PMID:35216460. IF:5.600(Q1/3D).
01/02/2022
"The Accessory Ethmoidal Canal Does Not Necessarily Contain an Arterial Structure"
Gras-Cabrerizo, JR, Martel-Martin, M, Villatoro-Sologaistoa, JC, De la Torre, FR, Mirapeix, R, Carrera, A, Montserrat-Gili, JR, Pujol-Olmo, A, Massegur-Solench, H. "The Accessory Ethmoidal Canal Does Not Necessarily Contain an Arterial Structure". ENT-EAR NOSE & THROAT JOURNAL. 2022; 101(2_SUPPL)DOI:10.1177/01455613211049656. PMID:34666559. IF:1.300(Q4/9D).
01/02/2022
Prognostic value of the nodal yield in elective neck dissections in patients with head and neck carcinomas
Leon, X, Venegas, MD, Casasayas, M, Rodriguez, C, Neumann, ED, Holgado, A, Quer, M. Prognostic value of the nodal yield in elective neck dissections in patients with head and neck carcinomas. EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY. 2022; 279(2)DOI:10.1007/s00405-021-06819-0. PMID:33938992. IF:2.600(Q2/3D).
01/02/2022
Daratumumab may be the most effective treatment for post-engraftment pure red cell aplasia due to persistent anti-donor isohemagglutinins after major ABO-mismatched allogeneic transplantation
Martino, R, Garcia-Cadenas, I, Esquirol, A. Daratumumab may be the most effective treatment for post-engraftment pure red cell aplasia due to persistent anti-donor isohemagglutinins after major ABO-mismatched allogeneic transplantation. BONE MARROW TRANSPLANTATION. 2022; 57(2)DOI:10.1038/s41409-021-01507-3. PMID:34711914. IF:4.800(Q1/2D).
01/02/2022
Revised International Prognostic Index and genetic alterations are associated with early failure to R-CHOP in patients with diffuse large B-cell lymphoma
Dlouhy, I, Karube, K, Enjuanes, A, Salaverria, I, Nadeu, F, Ramis-Zaldivar, JE, Valero, JG, Rivas-Delgado, A, Magnano, L, Martin-Garcia, D, Perez-Galan, P, Clot, G, Rovira, J, Jares, P, Balague, O, Gine, E, Mozas, P, Briones, J, Sancho, JM, Salar, A, Mercadal, S, Alcoceba, M, Valera, A, Campo, E, Lopez-Guillermo, A. Revised International Prognostic Index and genetic alterations are associated with early failure to R-CHOP in patients with diffuse large B-cell lymphoma. BRITISH JOURNAL OF HAEMATOLOGY. 2022; 196(3)DOI:10.1111/bjh.17858. PMID:34632572. IF:6.500(Q1/3D).
01/02/2022
Prognostic heterogeneity of adult B-cell precursor acute lymphoblastic leukaemia patients with t(1;19)(q23;p13)/ TCF3-PBX1 treated with measurable residual disease-oriented protocols
Ribera, J, Granada, I, Morgades, M, Gonzalez, T, Ciudad, J, Such, E, Calasanz, MJ, Mercadal, S, Coll, R, Gonzalez-Campos, J, Tormo, M, Garcia-Cadenas, I, Gil, C, Cervera, M, Barba, P, Costa, D, Ayala, R, Bermudez, A, Orfao, A, Ribera, JM. Prognostic heterogeneity of adult B-cell precursor acute lymphoblastic leukaemia patients with t(1;19)(q23;p13)/ TCF3-PBX1 treated with measurable residual disease-oriented protocols. BRITISH JOURNAL OF HAEMATOLOGY. 2022; 196(3)DOI:10.1111/bjh.17844. PMID:34549416. IF:6.500(Q1/3D).
01/02/2022
Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials
Allan, JN, Shanafelt, T, Wiestner, A, Moreno, C, O'Brien, SM, Li, JL, Krigsfeld, G, Dean, JP, Ahn, IE. Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials. BRITISH JOURNAL OF HAEMATOLOGY. 2022; 196(4)DOI:10.1111/bjh.17984. PMID:34865212. IF:6.500(Q1/3D).
01/02/2022
Efficacy and safety assessment of prolonged maintenance with subcutaneous rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: results of the phase Ill MabCute study
Rule, S, Barreto, WG, Briones, J, Carella, AM, Casasnovas, O, Pocock, C, Wendtner, CM, Zaja, F, Robson, S, MacGregor, L, Tschopp, RR, Nick, S, Dreyling, M. Efficacy and safety assessment of prolonged maintenance with subcutaneous rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: results of the phase Ill MabCute study. HAEMATOLOGICA. 2022; 107(2)DOI:10.3324/haematol.2020.274803. PMID:34134469. IF:10.100(Q1/2D).